Transaction Details

Footnotes

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4. | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.315 to $1.32, inclusive. | The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.305 to $1.32, inclusive. | Includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner.